ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

PHASE4CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2010

Conditions

HIV Infections

Interventions

DRUG

Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg

Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.

Trial Locations (1)

Gilead Sciences, Cambridge